ArticleCNS neuroscience & therapeutics2026
Neuroprotective Role of E3 Ubiquitin Ligase TRIM2 in Parkinson's Disease: Attenuation of Oxidative Stress and Apoptosis via Promoting ELAVL1 Ubiquitination.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons, where oxidative stress and neuronal apoptosis are key pathogenic events. In this study, we identified a downregulated TRIM2 in the substantia nigra pars compacta (SNc) of PD rats based on label-free proteomics. However, the impact of TRIM2 on PD is unknown.
methodsWe used 6-hydroxydopamine (6-OHDA) to construct a PD model in vivo and in vitro.
resultsTRIM2 overexpression alleviated neurobehavioral deficits, mitigated the loss of dopaminergic neurons, and suppressed oxidative stress and apoptosis in the SNc of PD rats. These effects were also observed in the 6-OHDA-treated differentiated BE (2)-M17 cells. Mechanistically, the RNA-binding protein ELAVL1 was identified as a critical downstream target, given that the database predicts it to be a TRIM2-interacted protein and a PD-related protein. Herein, TRIM2 directly interacted with ELAVL1 and promoted its ubiquitin-mediated degradation. Crucially, rescue experiments confirmed that the neuroprotection conferred by TRIM2 was counteracted by ELAVL1 overexpression in the 6-OHDA-treated BE (2)-M17 cells that exhibited neuronal-like properties.
conclusionOur findings uncovered a novel TRIM2-ELAVL1 axis as a pivotal regulatory mechanism in PD pathogenesis, positioning TRIM2 as a potential target for therapeutic intervention in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.